JO3735B1 - مركبات ألكين بها استبدال رباعي واستخداماتها - Google Patents
مركبات ألكين بها استبدال رباعي واستخداماتهاInfo
- Publication number
- JO3735B1 JO3735B1 JOP/2016/0102A JOP20160102A JO3735B1 JO 3735 B1 JO3735 B1 JO 3735B1 JO P20160102 A JOP20160102 A JO P20160102A JO 3735 B1 JO3735 B1 JO 3735B1
- Authority
- JO
- Jordan
- Prior art keywords
- compounds
- breast cancer
- alkene compounds
- tetrasubstituted alkene
- subject
- Prior art date
Links
- -1 alkene compounds Chemical class 0.000 title 1
- 206010006187 Breast cancer Diseases 0.000 abstract 3
- 208000026310 Breast neoplasm Diseases 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 2
- 102100038595 Estrogen receptor Human genes 0.000 abstract 1
- 101710196141 Estrogen receptor Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/02—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/02—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 2
- C07D317/06—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 2 condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
Abstract
يتعلق الاختراع الحالي بالكشف عن مركبات، أو أملاح مقبولة صيدلانياً منها، وطرق استخدام المركبات لمعالجة سرطان الثدي بواسطة إعطاء الخاضع الذي بحاجة إلى العلاج كمية فعالة صيدلانياً من المركبات أو الأملاح المقبولة صيدلانياً منها. يمكن أن يكون سرطان الثدي هو سرطان ثدي إيجابي لـ ER و/أو يمكن أن يعبر الخاضع الذي بحاجة إلى المعالجة عن بروتين ER-? به طفرة.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562168529P | 2015-05-29 | 2015-05-29 | |
| US201562168581P | 2015-05-29 | 2015-05-29 | |
| US201562269745P | 2015-12-18 | 2015-12-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JO3735B1 true JO3735B1 (ar) | 2021-01-31 |
Family
ID=57398096
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2016/0102A JO3735B1 (ar) | 2015-05-29 | 2016-05-29 | مركبات ألكين بها استبدال رباعي واستخداماتها |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US9796683B2 (ar) |
| EP (2) | EP3302471B1 (ar) |
| JP (1) | JP6325760B1 (ar) |
| CN (2) | CN107847498B (ar) |
| AU (1) | AU2016271126B2 (ar) |
| BR (1) | BR112017025546B1 (ar) |
| CA (1) | CA2987321C (ar) |
| CL (1) | CL2017002996A1 (ar) |
| CO (1) | CO2017013432A2 (ar) |
| CY (1) | CY1125068T1 (ar) |
| DK (1) | DK3302471T3 (ar) |
| ES (1) | ES2895511T3 (ar) |
| HR (1) | HRP20211542T1 (ar) |
| HU (1) | HUE056199T2 (ar) |
| IL (1) | IL255765B2 (ar) |
| JO (1) | JO3735B1 (ar) |
| LT (1) | LT3302471T (ar) |
| MA (1) | MA43364B1 (ar) |
| MD (1) | MD3302471T2 (ar) |
| MX (1) | MX2017015226A (ar) |
| MY (1) | MY186977A (ar) |
| PE (1) | PE20181083A1 (ar) |
| PH (1) | PH12017502142A1 (ar) |
| PL (1) | PL3302471T3 (ar) |
| PT (1) | PT3302471T (ar) |
| RS (1) | RS62481B1 (ar) |
| RU (1) | RU2733741C2 (ar) |
| SI (1) | SI3302471T1 (ar) |
| TW (1) | TWI704137B (ar) |
| UA (1) | UA120882C2 (ar) |
| WO (2) | WO2016196346A1 (ar) |
| ZA (1) | ZA201707912B (ar) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107847498B (zh) | 2015-05-29 | 2021-04-13 | 卫材R&D管理有限公司 | 四取代的烯烃化合物及其用途 |
| US20190337921A1 (en) * | 2016-11-24 | 2019-11-07 | Eisai R&D Management Co., Ltd. | Tetrasubstituted alkene compounds and their use |
| WO2018098305A1 (en) | 2016-11-24 | 2018-05-31 | Eisai R&D Management Co., Ltd. | Tetrasubstituted alkene compounds and their use for the treatment of breast cancer |
| CA3041986A1 (en) * | 2016-11-28 | 2018-05-31 | Eisai R&D Management Co., Ltd. | Salts of indazole derivative and crystals thereof |
| WO2018170447A1 (en) | 2017-03-16 | 2018-09-20 | Eisai R&D Management Co., Ltd. | Combination therapies for the treatment of breast cancer |
| WO2019225552A1 (en) * | 2018-05-22 | 2019-11-28 | Eisai R&D Management Co., Ltd. | Salts of indazole derivative and crystals thereof |
| US20220033376A1 (en) * | 2018-12-17 | 2022-02-03 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Estrogen receptor antagonist |
| KR20220008869A (ko) * | 2019-05-14 | 2022-01-21 | 누베이션 바이오 인크. | 항암 핵 호르몬 수용체-표적화 화합물 |
| US20220226300A1 (en) | 2019-05-24 | 2022-07-21 | Eisai R&D Management Co., Ltd. | A method for treating cancer with an oral dosage form of an estrogen receptor-alpha inhibitor |
| WO2020253762A1 (zh) | 2019-06-19 | 2020-12-24 | 江苏恒瑞医药股份有限公司 | 吲唑类衍生物、其制备方法及其在医药上的应用 |
| CN110452177A (zh) * | 2019-09-02 | 2019-11-15 | 南通大学 | 一种5-溴-4-氟-1h-吲唑的合成方法 |
| US11952349B2 (en) | 2019-11-13 | 2024-04-09 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| JP7419575B2 (ja) | 2020-06-28 | 2024-01-22 | メッドシャイン ディスカバリー インコーポレイテッド | 縮合環インダゾール系化合物 |
| US20230404987A1 (en) * | 2020-11-06 | 2023-12-21 | Eisai R&D Management Co., Ltd. | Method of treating breast cancer |
| WO2022127904A1 (zh) * | 2020-12-18 | 2022-06-23 | 江苏恒瑞医药股份有限公司 | 一种吲唑类衍生物的药学上可接受的盐、结晶形式及其制备方法 |
| CN114644615B (zh) * | 2020-12-18 | 2023-11-14 | 江苏恒瑞医药股份有限公司 | 一种吲唑类衍生物的结晶形式及其制备方法 |
| CN114644616B (zh) * | 2020-12-18 | 2023-11-14 | 江苏恒瑞医药股份有限公司 | 一种吲唑类衍生物的药学上可接受的盐、结晶形式及其制备方法 |
| US11834458B2 (en) | 2021-03-23 | 2023-12-05 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| WO2023272410A1 (zh) * | 2021-06-27 | 2023-01-05 | 北京盛诺基医药科技股份有限公司 | 一种ERα受体共价结合拮抗剂 |
| CN115960082A (zh) * | 2021-10-13 | 2023-04-14 | 长春金赛药业有限责任公司 | 一种四取代的烯烃化合物、其制备方法及其在医药上的应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3907290A1 (de) | 1989-03-07 | 1990-09-13 | Gerhard Prof Dr Eisenbrand | Steroidhormonrezeptoraffine antitumorwirkstoffe |
| US5552412A (en) | 1995-01-09 | 1996-09-03 | Pfizer Inc | 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis |
| TW397821B (en) * | 1996-04-19 | 2000-07-11 | American Home Produits Corp | 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof |
| US6897231B2 (en) * | 2000-07-31 | 2005-05-24 | Signal Pharmaceuticals, Inc. | Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
| WO2007058626A1 (en) * | 2005-11-16 | 2007-05-24 | S*Bio Pte Ltd | Indazole compounds |
| WO2009120999A2 (en) | 2008-03-28 | 2009-10-01 | Olema Pharmaceuticals, Inc. | Use of an endoxifen prodrug for treatment of breast cancer |
| US8063249B1 (en) * | 2008-04-25 | 2011-11-22 | Olema Pharmaceuticals, Inc. | Substituted triphenyl butenes |
| US8785501B2 (en) | 2009-10-13 | 2014-07-22 | Duquesne University Of The Holy Spirit | Anti-cancer tamoxifen-melatonin hybrid ligand |
| WO2011129837A1 (en) | 2010-04-16 | 2011-10-20 | Olema Pharmaceuticals, Inc. | Use of a 4-hydroxytoremifene prodrug for treatment of breast cancer |
| GB2483736B (en) | 2010-09-16 | 2012-08-29 | Aragon Pharmaceuticals Inc | Estrogen receptor modulators and uses thereof |
| WO2013056178A2 (en) | 2011-10-14 | 2013-04-18 | Foundation Medicine, Inc. | Novel estrogen receptor mutations and uses thereof |
| PE20142461A1 (es) | 2012-03-20 | 2015-02-05 | Seragon Pharmaceuticals Inc | Moduladores del receptor de estrogeno y sus usos |
| US9365510B2 (en) | 2012-04-16 | 2016-06-14 | British Columbia Cancer Agency Branch | Aziridine bisphenol ethers and related compounds and methods for their use |
| JOP20200097A1 (ar) | 2013-01-15 | 2017-06-16 | Aragon Pharmaceuticals Inc | معدل مستقبل أندروجين واستخداماته |
| JP6389517B2 (ja) | 2013-06-19 | 2018-09-12 | セラゴン ファーマシューティカルズ， インク． | アゼチジンエストロゲン受容体調節因子及びその使用 |
| SG11201509508YA (en) | 2013-06-19 | 2015-12-30 | Seragon Pharmaceuticals Inc | Estrogen receptor modulator and uses thereof |
| GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| CN106572990A (zh) | 2014-03-13 | 2017-04-19 | 豪夫迈·罗氏有限公司 | 含有雌激素受体调节剂的治疗性组合产品 |
| WO2016055982A1 (en) | 2014-10-10 | 2016-04-14 | Acerta Pharma B.V. | Quinoline and quinazoline compounds |
| WO2016097071A1 (en) | 2014-12-18 | 2016-06-23 | F. Hoffmann-La Roche Ag | Estrogen receptor modulators and uses thereof |
| CN107847498B (zh) | 2015-05-29 | 2021-04-13 | 卫材R&D管理有限公司 | 四取代的烯烃化合物及其用途 |
-
2016
- 2016-05-27 CN CN201680043755.7A patent/CN107847498B/zh active Active
- 2016-05-27 RS RS20211306A patent/RS62481B1/sr unknown
- 2016-05-27 HR HRP20211542TT patent/HRP20211542T1/hr unknown
- 2016-05-27 BR BR112017025546-4A patent/BR112017025546B1/pt active IP Right Grant
- 2016-05-27 EP EP16804153.1A patent/EP3302471B1/en active Active
- 2016-05-27 CA CA2987321A patent/CA2987321C/en active Active
- 2016-05-27 HU HUE16804153A patent/HUE056199T2/hu unknown
- 2016-05-27 MX MX2017015226A patent/MX2017015226A/es unknown
- 2016-05-27 MA MA43364A patent/MA43364B1/fr unknown
- 2016-05-27 WO PCT/US2016/034782 patent/WO2016196346A1/en active Application Filing
- 2016-05-27 LT LTEPPCT/US2016/034782T patent/LT3302471T/lt unknown
- 2016-05-27 EP EP21191181.3A patent/EP3981766A1/en not_active Withdrawn
- 2016-05-27 US US15/167,373 patent/US9796683B2/en active Active
- 2016-05-27 CN CN202110301494.7A patent/CN113024466A/zh active Pending
- 2016-05-27 SI SI201631340T patent/SI3302471T1/sl unknown
- 2016-05-27 PT PT168041531T patent/PT3302471T/pt unknown
- 2016-05-27 JP JP2017560920A patent/JP6325760B1/ja active Active
- 2016-05-27 DK DK16804153.1T patent/DK3302471T3/da active
- 2016-05-27 IL IL255765A patent/IL255765B2/en unknown
- 2016-05-27 ES ES16804153T patent/ES2895511T3/es active Active
- 2016-05-27 MY MYPI2017001740A patent/MY186977A/en unknown
- 2016-05-27 WO PCT/US2016/034764 patent/WO2016196337A1/en active Application Filing
- 2016-05-27 RU RU2017146408A patent/RU2733741C2/ru active
- 2016-05-27 PL PL16804153T patent/PL3302471T3/pl unknown
- 2016-05-27 MD MDE20180368T patent/MD3302471T2/ro unknown
- 2016-05-27 UA UAA201712962A patent/UA120882C2/uk unknown
- 2016-05-27 PE PE2017002481A patent/PE20181083A1/es unknown
- 2016-05-27 AU AU2016271126A patent/AU2016271126B2/en active Active
- 2016-05-27 TW TW105116750A patent/TWI704137B/zh active
- 2016-05-29 JO JOP/2016/0102A patent/JO3735B1/ar active
-
2017
- 2017-09-22 US US15/713,107 patent/US10851065B2/en active Active
- 2017-11-21 ZA ZA2017/07912A patent/ZA201707912B/en unknown
- 2017-11-24 PH PH12017502142A patent/PH12017502142A1/en unknown
- 2017-11-27 CL CL2017002996A patent/CL2017002996A1/es unknown
- 2017-12-27 CO CONC2017/0013432A patent/CO2017013432A2/es unknown
-
2021
- 2021-11-08 CY CY20211100961T patent/CY1125068T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JO3735B1 (ar) | مركبات ألكين بها استبدال رباعي واستخداماتها | |
| MX2019005465A (es) | Metodo de tratamiento de un tumor inmunoterapeutico. | |
| PH12017550063A1 (en) | Combination therapies for treating cancers | |
| AU2017362418B2 (en) | Remnant tumor infiltrating lymphocytes and methods of preparing and using the same | |
| PH12016502354A1 (en) | Pharmaceutical composition | |
| SG10201811841UA (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
| MX2018006674A (es) | Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control. | |
| TW201613636A (en) | Methods of treating Alzheimer's Disease | |
| MX2015010791A (es) | Metodos para tratar el cancer y prevenir la resistencia a farmacos. | |
| IN2014MU00303A (ar) | ||
| MX2018005544A (es) | Uso de agonistas del receptor tipo toll- 8 (tlr8) para tratar cancer. | |
| PH12016502352A1 (en) | Pharmaceutical composition | |
| MX2017000366A (es) | Terapia de combinacion para el cancer. | |
| SA515370011B1 (ar) | طرق لعلاج سرطان باستخدام علاج توليفي من مركب داي هيدرو بيرازينو-بيرازين | |
| TW201613578A (en) | Pharmaceutical combinations | |
| MX2020001727A (es) | Terapia de combinacion. | |
| MX2016015378A (es) | Uso de eribulina en el tratamiento de cancer. | |
| SG10201804034QA (en) | Methods for treating hypotension | |
| PH12016502243A1 (en) | Pharmaceutical compositions for treating infectious diseases | |
| UA118474C2 (uk) | (s)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині | |
| MX2022014792A (es) | Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican. | |
| MX2018010223A (es) | Terapia combinada para tratamiento de cancer de ovario. | |
| NZ625758A (en) | Method for treating breast cancer | |
| PH12016501101A1 (en) | Veliparib in combination with carboplatin for the treatment of triple negative breast cancer | |
| MX2017013666A (es) | Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer. |